Apimeds Pharmaceuticals US, Inc. Sample Contracts

UNDERWRITING AGREEMENT between APIMEDS PHARMACEUTICALS US, INC. and EF HUTTON LLC as Representative of the Several Underwriters APIMEDS PHARMACEUTICALS US, INC.
Underwriting Agreement • September 25th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations • New York

The undersigned, Apimeds Pharmaceuticals US, Inc., a corporation formed under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Apimeds Pharmaceuticals US, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with EF Hutton LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:

Sample 1Sample 2Sample 3See All (1k)
AutoNDA by SimpleDocs
INDEMNIFICATION AGREEMENT
Indemnification Agreement • September 25th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations • Delaware

THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made as of , 2024, by and between Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).

Sample 1Sample 2Sample 3See All (308)
LOAN AGREEMENT THIS LOAN AGREEMENT dated this tenth day of November, 2022 between Christopher M Kim of 25 Edinburg Cir, Matawan, NJ 07747 (the “Lender”) and
Loan Agreement • September 25th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations • New Jersey

In consideration of the lender loaning certain monies (the Loan”) to the Borrower, and the Borrower repaying the Loan to the Lenser, the parties agree to keep, perform and fulfill the promises and conditions set out in this Agreement:

Sample 1Sample 2Sample 3See All (10)
PROMISSORY NOTE
Promissory Note Amendment • September 25th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations • Delaware

THIS AMENDMENT TO THE PROMISSORY NOTE by and between Apimeds Pharmaceuticals US, Inc. a Delaware corporation (the “Company”), and Apimeds Inc., a South Korean corporation (the “Holder”) is made and entered into as of December 5, 2023 (this “Amendment”).

Sample 1Sample 2Sample 3See All (7)
INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT
Intellectual Property Assignment Agreement • September 25th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations • Delaware

This INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT (this “Agreement”), dated October 12, 2021, effective as of May 12, 2020 (the “Effective Date”), is entered into by and among Kim Moon Ho a/k/a Chris MH Kim, MD, an individual (“Assignor”), Apimeds, Inc., a South Korea corporation (“Assignee”), and Apimeds Pharmaceuticals US, Inc., a Delaware corporation (“APUS”). Each of the Assignor, Assignee and APUS are herein referred to individually as a “Party” and together as the “Parties.”

Sample 1Sample 2Sample 3See All (4)
AMENDMENT TO THE AMENDMENT TO THE PROMISSORY NOTE
Amendment to the Promissory Note • September 25th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations

THIS AMENDMENT (this “Amendment”) to the Amendment to the Promissory Note, dated as of December 5, 2023 (the “Original Amendment”), which amended the Promissory Note, dated as of June 3, 2022, by and between Apimeds Pharmaceuticals US, Inc. a Delaware corporation (the “Company”) and Inscobee, Inc., a South Korean corporation (the “Holder”), is made and entered into as of June 12, 2024. All capitalized terms not specifically defined in this Amendment shall have the meanings ascribed to them in the Original Amendment.

Sample 1Sample 2Sample 3
MURDOCK CAPITAL PARTNERS CORP.
Consulting Agreement • September 25th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations

Pursuant to our recent conversations regarding the Think Equity capital raise and IPO Initial Public Offering - for Apimeds Pharmaceuticals US, Inc. (“Apimeds USA”) this letter is to acknowledge and confirm the terms of an advisory and corporate consulting fee agreement (the “consulting agreement”) as follows:

Sample 1Sample 2Sample 3
BUSINESS ESTABLISHMENT AGREEMENT
Business Establishment Agreement • September 25th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations

This Business Establishment Agreement (the “Agreement”) is made and entered into effective as of March 3, 2020 (the “Effective Date”), by and between Apimeds Korea (“Company”) and ApiMed USA, with a business located at 5 Caroline Dr, Princeton, NJ 08540 USA, (“Receiving Party”) a contemplated Delaware corporation with a place of business in the United States of America.

Sample 1Sample 2
APIMEDS PHARMACEUTICALS US, INC.
Supply Agreement • September 25th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations • Delaware

This letter agreement is intended to memorialize our mutual understanding with respect to our business relationship. You agree that, for a period of ten years from the date of this letter agreement, you will not supply Apis Mellifera venom for any pharmaceutical use to any party other than Apimeds Pharmaceuticals US, Inc.; provided you may supply to Apimeds, Inc. (Korea) for their use outside of the United States. This agreement specifically excludes customers using venom for immunology, cosmetic or any other "non-pharmaceutical" use.

Sample 1Sample 2
BUSINESS AGREEMENT
Business Agreement • September 25th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations

WHEREAS, the Parties have formed APUS to operate a pharmaceutical business which provides the biological drug named “Apitox” (“Apitox”) to clients in the biological drug commercial transaction area (the “Project”); and

Sample 1Sample 2
EXECUTVIE EMPLOYMENT AGREEMENT,
Executive Employment Agreement • September 25th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations

THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”), dated as of September 21, 2023 (“Effective Date”), is entered into by and between Apimeds Pharmaceutical US, Inc., a Delaware corporation having its principal place of business at 25 Edinburg Circle, Matawan, NJ 07747 (the “Company_”), and Erik Emerson an individual residing for the purposes set forth in this agreement in the State of New Jersey (“Executive”).

Sample 1Sample 2
PATENT LICENSE AGREEMENT
Patent License Agreement • September 25th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations • Delaware

This Patent License Agreement (“Agreement”), dated as of October 12, 2021 (the “Effective Date”), is by and between Kim Moon 1-lo a/k/a Chris MH Kim, MD, an individual (“Licensor”) and Apimeds Pharmaceuticals US, Inc., a Delaware corporation (“Licensee”) (each a “Party” and collectively, the “Parties”).

Sample 1Sample 2
PROMISSORY NOTE
Promissory Note Amendment • January 29th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations • Delaware

THIS AMENDMENT TO THE PROMISSORY NOTE by and between Apimeds Pharmaceuticals US, Inc. a Delaware corporation (the “Company”), and Apimeds Inc., a South Korean corporation (the “Holder”) is made and entered into as of December 5, 2023 (this “Amendment”).

Sample 1
EXECUTVIE EMPLOYMENT AGREEMENT,
Executive Employment Agreement • May 13th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations

THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”), dated as of September 21, 2023 (“Effective Date”), is entered into by and between Apimeds Pharmaceutical US, Inc., a Delaware corporation having its principal place of business at 25 Edinburg Circle, Matawan, NJ 07747 (the “Company_”), and Erik Emerson an individual residing for the purposes set forth in this agreement in the State of New Jersey (“Executive”).

Sample 1
LOAN AGREEMENT THIS LOAN AGREEMENT dated the 5th day October, 2022 between Christopher M Kim of 25 Edinburg Cir, Matawan, NJ 07747 (the “Lender”) and
Loan Agreement • January 29th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations • New Jersey

In consideration of the lender loaning certain monies (the Loan”) to the Borrower, and the Borrower repaying the Loan to the Lenser, the parties agree to keep, perform and fulfill the promises and conditions set out in this Agreement:

Sample 1
LOAN AGREEMENT THIS LOAN AGREEMENT dated this 16th day of March, 2023 between Christopher M Kim of 25 Edinburg Cir, Matawan, NJ 07747 (the “Lender”) and
Loan Agreement • January 29th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations • New Jersey

In consideration of the lender loaning certain monies (the Loan”) to the Borrower, and the Borrower repaying the Loan to the Lenser, the parties agree to keep, perform and fulfill the promises and conditions set out in this Agreement:

Sample 1
CFO CONSULTING AGREEMENT
Cfo Consulting Agreement • June 17th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations • New York

CFO CONSULTING AGREEMENT dated as of March 20, 2024 (this “Agreement”), between APIMEDS PHARMACEUTICALS US, INC., a Delaware Corporation, (the “Company”) with offices located at 125 Broemel Pl Ste 639, Pennington, NJ 08534, and James S. Cardwell (the “Consultant”).

Sample 1
UNDERWRITING AGREEMENT between APIMEDS PHARMACEUTICALS US, INC. and as Representative of the Several Underwriters APIMEDS PHARMACEUTICALS US, INC.
Underwriting Agreement • December 9th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations • New York

The undersigned, Apimeds Pharmaceuticals US, Inc., a corporation formed under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Apimeds Pharmaceuticals US, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with D. Boral Capital Securities, LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:

Sample 1
AMENDMENT TO THE PROMISSORY NOTE
Promissory Note Amendment • January 29th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations • Delaware

THIS AMENDMENT TO THE PROMISSORY NOTE by and between Apimeds Pharmaceuticals US, Inc. a Delaware corporation (the "Company"), and Apimeds Inc., a South Korean corporation (the “Holder”) is made and entered into as of December 5, 2023 (this “Amendment”).

Sample 1
Contract
Business Establishment Agreement • January 29th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations

This Business Establishment Agreement (the “Agreement”) is made and entered into effective as of March 3, 2020 (the “Effective Date”), by and between Apimeds Korea (“Company”) and ApiMed USA, with a business located at 5 Caroline Dr, Princeton, NJ 08540 USA, (“Receiving Party”) a contemplated Delaware corporation with a place of business in the United States of America.

Sample 1
CFO CONSULTING AGREEMENT
Cfo Consulting Agreement • November 8th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations • New York

CFO CONSULTING AGREEMENT dated as of October 4, 2024 (this “Agreement”), between APIMEDS PHARMACEUTICALS US, INC., a Delaware Corporation, (the “Company”) with offices located at 2 East Broad Street, 2nd Floor, Hopewell, NJ 08425, and Mark Corrao (the “Consultant”).

Sample 1
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!